İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
The Cooper Companies, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $10.5B |
|---|
| Revenue (ttm) | 4.2B |
|---|
| Net income (ttm) | 570.3M |
|---|
| EPS (ttm) | $2.90 |
|---|
| Shares out | 190.2M |
|---|
| P/E (trailing) | 20.4x |
|---|
| P/E (forward) | 11.3x |
|---|
| Volume | 2,944,052 |
|---|
| Beta | 0.83 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | Trend |
| Revenue | $2.92B | $3.31B | $3.59B | $3.90B | $4.09B | +8.8% |
| Gross profit | $1.96B | $2.14B | $2.36B | $2.60B | $2.68B | +8.2% |
| Operating income | $505.8M | $507.6M | $533.1M | $705.7M | $682.9M | +7.8% |
| Net income | $2.94B | $385.8M | $294.2M | $392.3M | $374.9M | -40.3% |
| EPS (diluted) | $14.79 | $1.94 | $1.48 | $1.96 | $1.87 | -40.4% |
| EBITDA | $823.9M | $878.7M | $885.9M | $1.07B | $1.05B | +6.3% |
| R&D | $92.7M | $110.3M | $137.4M | $155.1M | $172.2M | +16.7% |
| SG&A | $1.21B | $1.34B | $1.50B | $1.53B | $1.63B | +7.7% |
Recent company headlines from major financial publishers.
The Base case envisions steady compounding driven by ongoing conversion to premium daily disposable contact lenses, defensive gross margins, and gradual deleveraging. Performance tracks toward Fair value of $78.48, supported by stable replacement demand across optometry networks. The thesis would be challenged if European revenue decelerates or if surgical segment margins fail to recover.
The Bull case models accelerated market share gains in specialty silicone hydrogel daily lenses across Europe and Asia, accompanied by operational integration in Cooper Surgical that lifts segment margins. This outcome delivers Potential value of $92.70 as valuation multiples expand. Slower adoption of daily modalities would disconfirm this trajectory.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.7% | $96.5 | $103 | $111 | $122 | $136 |
| 7.7% | $82.6 | $86.6 | $91.5 | $97.5 | $105 |
| 8.7% | $72.7 | $75.3 | $78.5 | $82.2 | $86.7 |
| 9.7% | $65.1 | $67.0 | $69.2 | $71.7 | $74.6 |
| 10.7% | $59.2 | $60.6 | $62.1 | $63.9 | $65.9 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |